Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Options For Japan As More COVID-19 Vaccines Finally Approved

Nods For Moderna, AstraZeneca

Executive Summary

Japan has granted emergency approvals to two more vaccines for COVID-19, both from multinational developers, as it finally expands a so far very limited armory against the pandemic. 

You may also be interested in...



Ricks Renews PhRMA Call For Comprehensive Japan Policy Dialog

US research-based group again calls for a comprehensive dialog with all healthcare system stakeholders in Japan to address what it sees as "harmful" policies that have reduced the country's support for innovation and attractiveness as a market for drug development amid the rapid rise of some regional neighbors.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: Teva’s immunology biosimilar launches; Intra-Cellular’s promising depression data; Phase III sleep apnea win for Lilly’s tirzepatide; an interview with Viking’s CEO; and China looks to define innovative drugs.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS144358

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel